Resveratrol prevents the development of choroidal neovascularization by modulating AMP-activated protein kinase in macrophages and other cell types

Journal of Nutritional Biochemistry

Volumn 25, Issue 11, 2014, Pages 1218-1225

  Nagai, Norihiro ^a   Kubota, Shunsuke ^a   Tsubota, Kazuo ^a   Ozawa, Yoko ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AMPK; Inflammation; Macrophage; Neovascularization; Resveratrol; Retina

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; RESVERATROL; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; LASER COAGULATION; LOW LEVEL LASER THERAPY; MACROPHAGE; MACROPHAGE MIGRATION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PIGMENT CELL; PIGMENT EPITHELIUM; PREMEDICATION; PROPHYLAXIS; PROTEIN EXPRESSION; SUBRETINAL NEOVASCULARIZATION; ANIMAL; C57BL MOUSE; CELL MOTION; CHOROIDAL NEOVASCULARIZATION; DRUG EFFECTS; ENZYMOLOGY; INFLAMMATION; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELL MOVEMENT; CHOROIDAL NEOVASCULARIZATION; INFLAMMATION; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; RETINAL PIGMENT EPITHELIUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STILBENES;

EID: 84908243297     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2014.05.015     Document Type: Article

References (60)

1. Bressler N.M. Age-related macular degeneration is the leading cause of blindness. JAMA 2004, 291:1900-1901.
2. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006, 355:1419-1431.
3. Brown D.M., Kaiser P.K., Michels M., Soubrane G., Heier J.S., Kim R.Y., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006, 355:1432-1444.
4. Heier J.S., Brown D.M., Chong V., Korobelnik J.F., Kaiser P.K., Nguyen Q.D., et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012, 119:2537-2548.
5. Suzuki M., Nagai N., Izumi-Nagai K., Shinoda H., Koto T., Uchida A., et al. Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration. Br J Ophthalmol 2014. in press.
6. Caputo M., Zirpoli H., Di Benedetto R., De Nadai K., Tecce M.F. Perspectives of choroidal neovascularization therapy. Curr Drug Targets 2011, 12:234-242.
7. Age-Related Eye Disease Study 2 Research G Lutein+zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013, 309:2005-2015.
8. Tsutsumi C., Sonoda K.H., Egashira K., Qiao H., Hisatomi T., Nakao S., et al. The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. J Leukoc Biol 2003, 74:25-32.
9. Sakurai E., Taguchi H., Anand A., Ambati B.K., Gragoudas E.S., Miller J.W., et al. Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 2003, 44:2743-2749.
10. Nagai N., Oike Y., Izumi-Nagai K., Urano T., Kubota Y., Noda K., et al. Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization. Arterioscler Thromb Vasc Biol 2006, 26:2252-2259.
11. Nagai N., Oike Y., Izumi-Nagai K., Koto T., Satofuka S., Shinoda H., et al. Suppression of choroidal neovascularization by inhibiting Angiotensin-converting enzyme: minimal role of bradykinin. Invest Ophthalmol Vis Sci 2007, 48:2321-2326.
12. Izumi-Nagai K., Nagai N., Ozawa Y., Mihara M., Ohsugi Y., Kurihara T., et al. Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization. Am J Pathol 2007, 170:2149-2158.
13. Nowak J.Z. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006, 58:353-363.
14. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
15. Lin M.T., Yen M.L., Lin C.Y., Kuo M.L. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol 2003, 64:1029-1036.
16. Norata G.D., Marchesi P., Passamonti S., Pirillo A., Violi F., Catapano A.L. Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. Atherosclerosis 2007, 191:265-271.
17. Kim D., Nguyen M.D., Dobbin M.M., Fischer A., Sananbenesi F., Rodgers J.T., et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007, 26:3169-3179.
18. Kubota S., Kurihara T., Ebinuma M., Kubota M., Yuki K., Sasaki M., et al. Resveratrol prevents light-induced retinal degeneration via suppressing activator protein-1 activation. Am J Pathol 2010, 177:1725-1731.
19. Hung L.M., Su M.J., Chen J.K. Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms. Free Radic Biol Med 2004, 36:774-781.
20. Ungvari Z., Orosz Z., Rivera A., Labinskyy N., Xiangmin Z., Olson S., et al. Resveratrol increases vascular oxidative stress resistance. Am J Physiol Heart Circ Physiol 2007, 292:H2417-H2424.
21. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
22. Zhang B.B., Zhou G., Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009, 9:407-416.
23. Kubota S., Ozawa Y., Kurihara T., Sasaki M., Yuki K., Miyake S., et al. Roles of AMP-activated protein kinase in diabetes-induced retinal inflammation. Invest Ophthalmol Vis Sci 2011, 52:9142-9148.
24. Kanamori H., Takemura G., Goto K., Tsujimoto A., Ogino A., Takeyama T., et al. Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway. Am J Pathol 2013, 182:701-713.
25. Dolinsky V.W., Chakrabarti S., Pereira T.J., Oka T., Levasseur J., Beker D., et al. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim Biophys Acta 1832, 2013:1723-1733.
26. Lin J.N., Lin V.C., Rau K.M., Shieh P.C., Kuo D.H., Shieh J.C., et al. Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. J Agric Food Chem 2010, 58:1584-1592.
27. Izumi-Nagai K., Nagai N., Ohgami K., Satofuka S., Ozawa Y., Tsubota K., et al. Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization. Arterioscler Thromb Vasc Biol 2007, 27:2555-2562.
28. Izumi-Nagai K., Nagai N., Ohgami K., Satofuka S., Ozawa Y., Tsubota K., et al. Inhibition of choroidal neovascularization with an anti-inflammatory carotenoid astaxanthin. Invest Ophthalmol Vis Sci 2008, 49:1679-1685.
29. Satofuka S., Ichihara A., Nagai N., Noda K., Ozawa Y., Fukamizu A., et al. (Pro)renin receptor promotes choroidal neovascularization by activating its signal transduction and tissue renin-angiotensin system. Am J Pathol 2008, 173:1911-1918.
30. Mochimaru H., Nagai N., Hasegawa G., Kudo-Saito C., Yaguchi T., Usui Y., et al. Suppression of choroidal neovascularization by dendritic cell vaccination targeting VEGFR2. Invest Ophthalmol Vis Sci 2007, 48:4795-4801.
31. Sakurai E., Anand A., Ambati B.K., van Rooijen N., Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2003, 44:3578-3585.
32. Radisavljevic Z., Avraham H., Avraham S. Vascular endothelial growth factor up-regulates ICAM-1 expression via the phosphatidylinositol 3 OH-kinase/AKT/Nitric oxide pathway and modulates migration of brain microvascular endothelial cells. J Biol Chem 2000, 275:20770-20774.
33. Ochoa O., Sun D., Reyes-Reyna S.M., Waite L.L., Michalek J.E., McManus L.M., et al. Delayed angiogenesis and VEGF production in CCR2-/- mice during impaired skeletal muscle regeneration. Am J Physiol Regul Integr Comp Physiol 2007, 293:R651-R661.
34. Dasgupta B., Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A 2007, 104:7217-7222.
35. Salminen A., Hyttinen J.M., Kaarniranta K. AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan. J Mol Med 2011, 89:667-676.
36. Grisanti S., Tatar O. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 2008, 27:372-390.
37. Frampton J.E. Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration. Drugs Aging 2013, 30:331-358.
38. Apte R.S., Richter J., Herndon J., Ferguson T.A. Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med 2006, 3:e310.
39. Ferguson T.A., Apte R.S. Angiogenesis in eye disease: immunity gained or immunity lost?. Semin Immunopathol 2008, 30:111-119.
40. Zhao H., Roychoudhury J., Doggett T.A., Apte R.S., Ferguson T.A. Age-dependent changes in FasL (CD95L) modulate macrophage function in a model of age-related macular degeneration. Invest Ophthalmol Vis Sci 2013, 54:5321-5331.
41. Suzuki M., Tsujikawa M., Itabe H., Du Z.J., Xie P., Matsumura N., et al. Chronic photo-oxidative stress and subsequent MCP-1 activation as causative factors for age-related macular degeneration. J Cell Sci 2012, 125:2407-2415.
42. Yamada K., Sakurai E., Itaya M., Yamasaki S., Ogura Y. Inhibition of laser-induced choroidal neovascularization by atorvastatin by downregulation of monocyte chemotactic protein-1 synthesis in mice. Invest Ophthalmol Vis Sci 2007, 48:1839-1843.
43. Hirano Y., Sakurai E., Matsubara A., Ogura Y. Suppression of ICAM-1 in retinal and choroidal endothelial cells by plasmid small-interfering RNAs in vivo. Invest Ophthalmol Vis Sci 2010, 51:508-515.
44. Killingsworth M.C., Sarks J.P., Sarks S.H. Macrophages related to Bruch's membrane in age-related macular degeneration. Eye 1990, 4(Pt. 4):613-621.
45. van der Schaft T.L., Mooy C.M., de Bruijn W.C., de Jong P.T. Early stages of age-related macular degeneration: an immunofluorescence and electron microscopy study. Br J Ophthalmol 1993, 77:657-661.
46. Imler T.J., Petro T.M. Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+ IL-10+ T cells, CD4(-) IFN-gamma+ cells, and decreased macrophage IL-6 expression. Int Immunopharmacol 2009, 9:134-143.
47. Izumi-Nagai K., Nagai N., Ozawa Y., Mihara M., Ohsugi Y., Kurihara T., et al. Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization. Am J Pathol 2007, 170:2149-2158.
48. Lavalette S., Raoul W., Houssier M., Camelo S., Levy O., Calippe B., et al. Interleukin-1beta inhibition prevents choroidal neovascularization and does not exacerbate photoreceptor degeneration. Am J Pathol 2011, 178:2416-2423.
49. Zong Y., Sun L., Liu B., Deng Y.S., Zhan D., Chen Y.L., et al. Resveratrol inhibits LPS-induced MAPKs activation via activation of the phosphatidylinositol 3-kinase pathway in murine RAW 264.7 macrophage cells. PLoS One 2012, 7:e44107.
50. Srivastava R.A., Pinkosky S.L., Filippov S., Hanselman J.C., Cramer C.T., Newton R.S. AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J Lipid Res 2012, 53:2490-2514.
51. Age-Related Eye Disease Study Research G A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol 2001, 119:1439-1452.
52. Khan A.A., Dace D.S., Ryazanov A.G., Kelly J., Apte R.S. Resveratrol regulates pathologic angiogenesis by a eukaryotic elongation factor-2 kinase-regulated pathway. Am J Pathol 2010, 177:481-492.
53. Sheu S.J., Liu N.C., Ou C.C., Bee Y.S., Chen S.C., Lin H.C., et al. Resveratrol stimulates mitochondrial bioenergetics to protect retinal pigment epithelial cells from oxidative damage. Invest Ophthalmol Vis Sci 2013, 54:6426-6438.
54. Giri S., Nath N., Smith B., Viollet B., Singh A.K., Singh I. 5-Aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J Neurosci 2004, 24:479-487.
55. Bai A., Yong M., Ma A.G., Ma Y., Weiss C.R., Guan Q., et al. Novel anti-inflammatory action of 5-aminoimidazole-4-carboxamide ribonucleoside with protective effect in dextran sulfate sodium-induced acute and chronic colitis. J Pharmacol Exp Ther 2010, 333:717-725.
56. Zhao X., Zmijewski J.W., Lorne E., Liu G., Park Y.J., Tsuruta Y., et al. Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2008, 295:L497-L504.
57. Pilon G., Dallaire P., Marette A. Inhibition of inducible nitric-oxide synthase by activators of AMP-activated protein kinase: a new mechanism of action of insulin-sensitizing drugs. J Biol Chem 2004, 279:20767-20774.
58. Saint-Geniez M., Kurihara T., Sekiyama E., Maldonado A.E., D'Amore P.A. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A 2009, 106:18751-18756.
59. Nishijima K., Ng Y.S., Zhong L., Bradley J., Schubert W., Jo N., et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007, 171:53-67.
60. Suzuki M., Ozawa Y., Kubota S., Hirasawa M., Miyake S., Noda K., et al. Neuroprotective response after photodynamic therapy: role of vascular endothelial growth factor. J Neuroinflammation 2011, 8:176.